Triptorelin: Difference between revisions

Latest revision as of 03:46, 13 February 2025

Overview[edit]

Triptorelin is a gonadotropin-releasing hormone agonist (GnRH agonist) used in the treatment of hormone-sensitive conditions such as prostate cancer, endometriosis, and precocious puberty. It is a synthetic decapeptide analog of the natural GnRH, which is involved in the regulation of the pituitary gland's secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

Mechanism of Action[edit]

Triptorelin acts by initially stimulating the release of LH and FSH from the pituitary gland, leading to a temporary increase in testosterone and estrogen levels. However, with continuous administration, it causes downregulation of the GnRH receptors in the pituitary, resulting in decreased secretion of LH and FSH. This leads to a significant reduction in the production of sex hormones, such as testosterone in men and estrogen in women, which is beneficial in treating hormone-sensitive conditions.

Clinical Uses[edit]

Triptorelin is primarily used in the management of:

Prostate cancer: By reducing testosterone levels, triptorelin helps in slowing the growth of hormone-sensitive prostate cancer.
Endometriosis: It alleviates symptoms by decreasing estrogen levels, which reduces the growth of endometrial tissue.
Precocious puberty: Triptorelin is used to delay the onset of puberty in children with this condition by suppressing the premature release of sex hormones.

Administration[edit]

Triptorelin is administered via intramuscular injection. The dosing schedule can vary depending on the condition being treated, with formulations available for monthly or quarterly administration.

Side Effects[edit]

Common side effects of triptorelin include:

Hot flashes
Decreased libido
Fatigue
Mood changes
Injection site reactions

In men, there may be an initial "flare" of symptoms due to the temporary increase in testosterone levels before they decrease.

Related Pages[edit]

@@ Line 1: / Line 1: @@
+{{DISPLAYTITLE:Triptorelin}}
-{{intro}}
+== Overview ==
-Triptorelin is a gonadotropin releasing hormone (GnRH) agonist that is a potent inhibitor of the synthesis of testosterone (in men) and estrogen (in women) and is used to treat advanced prostate cancer.
+[[File:Triptorelin.svg|thumb|right|Chemical structure of Triptorelin]]
+'''Triptorelin''' is a [[gonadotropin-releasing hormone agonist]] (GnRH agonist) used in the treatment of hormone-sensitive conditions such as [[prostate cancer]], [[endometriosis]], and [[precocious puberty]]. It is a synthetic decapeptide analog of the natural GnRH, which is involved in the regulation of the [[pituitary gland]]'s secretion of [[luteinizing hormone]] (LH) and [[follicle-stimulating hormone]] (FSH).
-{{livtox}}
+== Mechanism of Action ==
-Triptorelin is associated with a low rate of transient serum enzyme elevations during therapy, but has not been linked convincingly to cases of clinically apparent acute [[liver injury]].
+Triptorelin acts by initially stimulating the release of LH and FSH from the pituitary gland, leading to a temporary increase in [[testosterone]] and [[estrogen]] levels. However, with continuous administration, it causes downregulation of the GnRH receptors in the pituitary, resulting in decreased secretion of LH and FSH. This leads to a significant reduction in the production of sex hormones, such as testosterone in men and estrogen in women, which is beneficial in treating hormone-sensitive conditions.
-{{moa}}
-Triptorelin (trip" toe rel' in) is a decapeptide analogue of gonadotropin releasing hormone (GnRH) that acts on the pituitary to cause the synthesis and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH), two gonadotropins that act on the male testes to stimulate the production of testosterone and on the female ovaries to induce synthesis of estrogen.  Triptorelin and other GnRH agonists cause an initial surge of gonadotropin release, but then lead to down-regulation of their synthesis and secretion which results in a decline in testosterone and estrogen production.  Triptorelin, alone or in combination with other antiandrogens, has been found to be palliative in advanced prostate cancer and as effective as surgical castration.
-{{fda}}
+== Clinical Uses ==
-Triptorelin was approved for use in the United States for prostate cancer in 2000 and is still widely used, being considered a first line [[treatment]] of this hormone responsive malignancy.  Triptorelin is available generically and under the brand name Trelstar in an injectable suspension for intramuscular depot administration every 4 weeks (3.75 mg), 12 weeks (11.25 mg) or 24 weeks (22.5 mg).  Triptorelin and the other GnRH analogues cause a profound hypogonadism ("chemical castration").
+Triptorelin is primarily used in the management of:
-{{se}}
+* [[Prostate cancer]]: By reducing testosterone levels, triptorelin helps in slowing the growth of hormone-sensitive prostate cancer.
-The common [[side effects]] are typical of androgen deprivation, including hot flashes, loss of libido, erectile dysfunction, depression, [[nausea]], [[diarrhea]], weight gain and fluid retention.  Rare, but potentially severe adverse events can include immediate hypersensitivity reactions, pituitary apoplexy and, with long term use, weight gain, metabolic changes, diabetes and osteoporosis.
+* [[Endometriosis]]: It alleviates symptoms by decreasing estrogen levels, which reduces the growth of endometrial tissue.
+* [[Precocious puberty]]: Triptorelin is used to delay the onset of puberty in children with this condition by suppressing the premature release of sex hormones.
-{{cancer drugs}}
+== Administration ==
-{{coststubd}}
+Triptorelin is administered via [[intramuscular injection]]. The dosing schedule can vary depending on the condition being treated, with formulations available for monthly or quarterly administration.
+== Side Effects ==
+Common side effects of triptorelin include:
+* Hot flashes
+* Decreased libido
+* Fatigue
+* Mood changes
+* Injection site reactions
+In men, there may be an initial "flare" of symptoms due to the temporary increase in testosterone levels before they decrease.
+== Related Pages ==
+* [[Gonadotropin-releasing hormone]]
+* [[Luteinizing hormone]]
+* [[Follicle-stimulating hormone]]
+* [[Prostate cancer]]
+* [[Endometriosis]]
+* [[Precocious puberty]]
+[[Category:Hormonal agents]]
+[[Category:Peptides]]
+[[Category:Oncology]]